ALVO Stock Analysis: Buy, Sell, or Hold?
ALVO - Alvotech Ordinary Shares
$5.21
-0.11 (-2.07%)
▼
5d:
-1.88%
30d:
+4.2%
90d:
-31.9%
BUY
HIGH Confidence
Last Updated: February 3, 2026
Earnings: Mar 25, 2026
Get Alerted When ALVO Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: ALVO shows strong fundamentals and good volume confirmation. Solid entry point despite slightly high pricing.
✅ BUY SIGNAL: ALVO shows strong fundamentals and good volume confirmation. Solid entry point despite slightly high pricing.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$6.01
Based on 7.0% avg growth
INTRINSIC VALUE TODAY
$3.73
Trading above fair value
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 12.5x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: ALVO is currently trading at $5.21, which is considered slightly high relative to its 30-day fair value range of $4.81 to $5.28. From a valuation perspective, the stock is trading at a premium (Forward PE: 15.2) compared to its historical average (12.5). At these levels, the market is pricing in 6.7% annual earnings growth.
Technical Outlook: Technically, ALVO is in a strong downtrend. Immediate support is located at $4.92, while resistance sits at $5.58.
Market Sentiment: ALVO has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $22.17 (+325.5%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, ALVO is in a strong downtrend. Immediate support is located at $4.92, while resistance sits at $5.58.
Market Sentiment: ALVO has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $22.17 (+325.5%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Fair Price Range
$4.81 -
$5.28
Company Quality Score
55/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
79.5%
All Signals
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 325.5% below Wall St target ($22.17)
- BULLISH: Expecting earnings turnaround to 6.7% growth with 10.6% revenue growth
Fair Price Analysis
30-Day Fair Range
$4.81 -
$5.28
Current vs Fair Value
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$4.93
Resistance Level
$5.58
Current Trend
Strong Downtrend
Fundamental Context
Forward P/E (Next Year Est.)
15.17
Wall Street Target
$22.17
(+325.5%)
Revenue Growth (YoY)
10.6%
Earnings Growth (YoY)
-58.4%
Profit Margin
12.1%
Valuation Premium vs History
+6.7% premium
PE vs Historical
15.2 vs 12.5
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+6.7%
(market-implied from PE analysis)
1-Year Target
$5.56
(+7%)
2-Year Target
$5.93
(+14%)
3-Year Target
$6.33
(+22%)
3-Yr Target (if PE normalizes)
(PE: 15→13)
PE COMPRESSION
$5.21
(+0%)
Earnings growth offset by PE compression
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (23x PE), but valuation improves significantly next year (15x PE) as earnings recover.
Trailing PE: 23.13 | Current EPS (TTM): $0.23
Bull Case
$8.74
(+68%)
Analyst growth 49.3%, PE expands to 25.4
Base Case
$7.94
(+53%)
Market implied 49.3%, PE stable at 23.1
Bear Case
$3.62
(-31%)
Severe decline -20.0%, PE contracts to 19.7
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Last updated: February 03, 2026 6:43 PM ET
Data refreshes hourly during market hours. Next update: 7:43 PM
Data refreshes hourly during market hours. Next update: 7:43 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ALVO showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$180 | 65 BUY |
|
ZTS
Zoetis Inc |
STRONG BUY
19 analysts |
$154 | 58 HOLD |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$83 | 57 HOLD |
|
BCRX
BioCryst Pharmaceuticals… |
STRONG BUY
12 analysts |
$22 | 57 HOLD |
|
TEVA
Teva Pharma Industries L… |
STRONG BUY
11 analysts |
$37 | 59 HOLD |
